+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 25Years - 50Years
FEMALE
ID07209917

Preventing Cervical Cancer in Women Co-Infected with HPV and HIV in India A Study Comparing a Nurse-Led Nutrition and Support Program to Standard Care

Led by University of California, Irvine · Updated on 2026-07-31

348

Participants Needed

4

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Cervical cancer is a significant health issue among women in India, especially those living with both human papillomavirus HPV and human immunodeficiency virus HIV. Women living with HIV have a higher risk of persistent high-risk HPV infection, which can lead to cervical cancer. Factors such as lack of HPV screening, depression, stigma, and malnutrition worsen this risk. This study aims to evaluate a nurse-led, peer counselor-supported nutrition-enhanced intervention called SAKHI HPV, designed to prevent cervical cancer among women co-infected with HPV and HIV. The study is a five-year randomized controlled trial comparing the SAKHI HPV intervention to an enhanced standard of care SOC. The SAKHI intervention includes eight group education sessions led by healthcare experts, weekly one-on-one peer counselor support, and referral to life skills training classes. The SOC group receives usual care plus three group sessions on wellness, nutrition, and HIVHPV health promotion. Participants are women living with HIV who test positive for HPV but negative on visual inspection with acetic acid VIA. The intervention lasts six months, with follow-up assessments at 6, 12, and 18 months. Participants undergo screening with self-collected HPV swabs and VIA tests. Those eligible are randomized to either study arm. Throughout the study, questionnaires on demographics, stigma, mental health, diet, and adherence are collected. Blood tests measure nutritional markers, CD4 count, and HIV viral load. Peer counselors maintain regular contact to support adherence and engagement. The primary outcome is persistence of high-risk HPV infection measured over 12 to 18 months. Secondary outcomes include changes in HIV viral load, CD4 count, and serum albumin levels. The total participation period is 18 months after enrollment.

CONDITIONS

Brief Title

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

Research Team

V

Veena Satyanarayana

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here